Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Third Generation ◽

Phase Ib ◽

Epidermal Growth ◽

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

10.1158/1538-7445.am2019-ct033 ◽

2019 ◽

Cited By ~ 3

Author(s):

Lecia V. Sequist ◽

Jong Seok Lee ◽

Ji-Youn Han ◽

Wu-Chou Su ◽

James Chih-Hsin Yang ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Third Generation ◽

Phase Ib ◽

Epidermal Growth ◽

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

10.1158/1538-7445.am2019-ct032 ◽

2019 ◽

Cited By ~ 3

Author(s):

Helena Yu ◽

Myung-Ju Ahn ◽

Sang-We Kim ◽

Byoung Chul Cho ◽

Lecia Sequist ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Ib ◽

Epidermal Growth ◽

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

10.1158/1538-7445.sabcs18-ct032 ◽

2019 ◽

Author(s):

Helena Yu ◽

Myung-Ju Ahn ◽

Sang-We Kim ◽

Byoung Chul Cho ◽

Lecia Sequist ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Ib ◽

Epidermal Growth ◽

Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽

10.1039/c8ra08161a ◽

2018 ◽

Vol 8 (70) ◽

pp. 40387-40394 ◽

Cited By ~ 13

Author(s):

Mohamed W. Attwa ◽

Adnan A. Kadi ◽

Hany W. Darwish ◽

Ali S. Abdelhameed

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Third Generation ◽

Epidermal Growth ◽

Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma

Surgery Today ◽

10.1007/s00595-011-4514-2 ◽

2011 ◽

Vol 41 (6) ◽

pp. 818-823 ◽

Cited By ~ 3

Author(s):

Daigo Kawano ◽

Tokujiro Yano ◽

Fumihiro Shoji ◽

Kensaku Ito ◽

Yosuke Morodomi ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Signal Activation ◽

Inhibitor Treatment

Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach

Annals of Translational Medicine ◽

10.21037/atm.2018.12.42 ◽

2019 ◽

Vol 7 (1) ◽

pp. 14-14 ◽

Cited By ~ 4

Author(s):

Francesco Cortiula ◽

Giovanna De Maglio ◽

Maria Giulia Cangi ◽

Lorenzo Gerratana ◽

Camilla Lisanti ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Third Generation ◽

Tailored Therapy ◽

Abstract C161: Modulation of thymidine phosphorylase (TP) expression in breast cancer cell lines exposed to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839

10.1158/1535-7163.targ-09-c161 ◽

2009 ◽

Author(s):

Maria Ait‐Tihyaty ◽

Zakaria Rachid ◽

Bertrand J. Jean‐Claude

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Thymidine Phosphorylase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Breast Cancer Cell Lines ◽

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3074 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3074-3074 ◽

Cited By ~ 7

Author(s):

S. Di Cosimo ◽

P. Matar ◽

F. Rojo ◽

M. Guzman ◽

S. Rodriguez ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

In silico study of 1-benzoyl-3-methylthiourea derivatives activity as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidates

Chemical Data Collections ◽

10.1016/j.cdc.2021.100741 ◽

2021 ◽

pp. 100741

Author(s):

Ruswanto Ruswanto ◽

Amir M. Miftah ◽

Daryono H. Tjahjono ◽

Siswandono

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

In Silico ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

In Silico Study ◽

Responses of Human Colorectal Tumor Cells to Treatment with the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib

Cancer Research ◽

10.1158/0008-5472.can-06-1000 ◽

2006 ◽

Vol 66 (15) ◽

pp. 7708-7715 ◽

Cited By ~ 28

Author(s):

Matthew P. Cunningham ◽

Hilary Thomas ◽

Zhen Fan ◽

Helmout Modjtahedi

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Colorectal Tumor ◽

Epidermal Growth ◽

Receptor Monoclonal Antibody